key: cord-0972874-0i5cdks5
authors: Wojcik, Iwona; Schmidt, David E.; de Neef, Lisa A.; Rab, Minke A. E.; Meek, Bob; de Weerdt, Okke; Wuhrer, Manfred; van der Schoot, C. Ellen; Zwaginga, Jaap J.; de Haas, Masja; Falck, David; Vidarsson, Gestur
title: A functional spleen contributes to afucosylated IgG in humans
date: 2021-12-15
journal: Sci Rep
DOI: 10.1038/s41598-021-03196-w
sha: 305b7b450f72ca56e72105171a58bcb4ab773eb8
doc_id: 972874
cord_uid: 0i5cdks5

As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses. In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens. During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region. These glycans are essential for mediating the induction of immune effector functions. Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis. To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography–mass spectrometry (LC–MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis. IgG-Fc fucosylation was consistently increased after splenectomy, while no effects for IgG-Fc galactosylation and sialylation were observed. An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses. Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls. Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.

. For this reason, pneumococcal vaccination, especially with protein conjugated vaccine, is highly recommended before splenectomy 9 . Antibodies represent a major effector mechanism of the adaptive immune system. Besides Fab-based affinity maturation, the effector functions of IgG antibodies are modified by N-linked glycosylation of the antibody Fc (fragment crystallizable) portion at position 297. The exact composition of this glycan branch can be affected in an antigen-specific manner [10] [11] [12] [13] . This, in turn, modifies the binding to complement component C1q and to the IgG Fc gamma receptor III (FcγRIII) on immune cells, and determines the complement activity and antibodydependent cellular cytotoxicity 14 . Afucosylated IgG display enhanced binding to FcγRIII expressed on CD16 + monocytes, macrophages, neutrophils and natural killer (NK) cells causing increased antibody-dependent cellular cytotoxicity 14 . An increase in the Fc galactosylation of IgG leads to increased C1q-mediated complement activation 14, 15 .

In autoimmune diseases, total serum IgG-Fc glycosylation is skewed, mostly with lowered galactosylation, and this is associated with increased disease progression, activity and symptoms severity [16] [17] [18] [19] . Why this occurs is unclear, as elevated galactosylation of antigen-specific IgG is known to elevate their complement activity potential 14, 15, 20 . However, a possible explanation of the association between the lowered total IgG galactosylation and autoimmune diseases, is that the decrease in total IgG galactosylation seems to increase systemic inflammation 19, 20 . Observations in Guillain-Barré syndrome and Kawasaki disease suggest that pre-treatment levels and normalization of Fc galactosylation and sialylation after treatment are associated with recovery 21, 22 . Interestingly, we found no biologically significant changes in IgG-Fc glycosylation were observed after CD20targeted rituximab treatment in immune thrombocytopenia (ITP) 23 .

For alloimmune responses, that is foreign antigens on cells such as platelets and anti-red blood cell antigens (RBC) in either pregnancy or after transfusion, we previously described a general reduction of antigen-specific IgG-Fc fucosylation, such as for anti-D and anti-Human Platelet Antigen-1a (HPA-1a) antibodies [24] [25] [26] . Importantly, immunization to these alloantigens, also generally require a functional spleen 27 , suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses. Similar afucosylated antigen-specific IgG responses have been observed in virus-specific IgG responses, such as for dengue virus, HIV, cytomegalovirus (CMV), hepatitis B virus (HBV), measles virus, mumps virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [11] [12] [13] 28, 29 , and now recently shown by us to be a hallmark of enveloped viral infections, a response that is mimicked by alloimmunizations 11 . In theory, IgG afucosylation results in a strong humoral immune response, targeting FcγRIIIa and FcγRIIIb, potentially giving strong myeloid FcγR-mediated responses 30 that can ultimately be particularly protective as proposed for HIV 31 . On the other hand, this strong reaction can also lead to exaggerated myeloid response with elevated proinflammatory cytokine production culminating in adverse clinical reactions, as seen in Dengue and COVID-19 responses 11, 28, 32 .

The reduction in fucosylation seen in immune response to enveloped viral infections and alloimmune mediated diseases is particularly strong to CMV and many of the anti-red blood cell antigens (e.g. Rhesus D) and human platelet antigens. What these antigen responses have in common is a dominant systemic response likely to occur in the spleen 27 .

In the present study, we investigated the role of the spleen on IgG-Fc glycosylation in a large cohort of individuals splenectomized due to trauma, or due to immune thrombocytopenia, or spherocytosis, to test the hypothesis that the spleen is a primary driver of afucosylated IgG responses in humans.

We studied the impact of splenectomy on IgG-Fc N-linked glycosylation by comparing patients who had undergone splenectomy to control groups with an intact spleen. A proportion of individuals were splenectomized after trauma (n = 38), but were otherwise healthy, whereas others were splenectomized due to hematological disease (ITP, n = 35; spherocytosis, n = 16) ( Table 1 ). All of the subgroups of healthy controls and ITP patients were comparable for age and sex distribution thus reducing the age-and sex-depended differences in IgG glycosylation. 

Total IgG was affinity purified from 254 patient plasma samples, subjected to tryptic digestion, and the resulting IgG Asn297-Fc glycopeptides were analyzed by liquid chromatography-mass spectrometry (LC-MS) (Fig. 1A) . Tryptic digestion of all four IgG subclasses (IgG1, IgG2, IgG3, IgG4) resulted in distinct peptide moieties (IgG1: EEQYNSTYR, IgG2/3: EEQFNSTFR, IgG4: EEQFNSTYR). Thus, IgG-Fc glycopeptides were separated and glycosylation patterns of individual subclasses IgG1, IgG4 as well as collective Fc glycosylation profiles of IgG2/IgG3 were analyzed by LC-MS. An example of an LC-MS sum spectrum of total IgG1 glycopeptides can be seen in Fig. 1B . Inability to distinguish between IgG2 and IgG3 glycosylation by our profiling method is due to the fact that the amino acid sequence of the tryptic peptide including the N297-glycosylation site is identical for both IgG subclasses (EEQFNSTFR) 33, 34 . For all samples, 37 glycoforms positively passed the analyte curation, 19, 10 and 8 glycoforms for IgG1, IgG2/3 and IgG4, respectively (see Supplementary Table S1 ). For further analysis, derived glycosylation traits were calculated, including bisection, fucosylation, galactosylation and sialylation (Fig. 1C , see Supplementary Table S2 for the calculations of the derived traits). It should be noted that we could not assess the minor amount of IgG4 afucosylation which is a common limitation of the applied method.

IgG-Fc glycosylation, we compared samples from three different patient groups with splenectomy with age-and sex-matched respective controls with an intact spleen. The three different splenectomized patient groups were 1) trauma-associated 2) ITP patients and 3) spherocytosis patients. For trauma splenectomized individuals, we observed a significantly higher median IgG1 fucosylation and IgG2/3 fucosylation when compared to healthy controls ( 

tion of ITP patients with healthy controls showed that the ITP patients had significantly lower median IgG1 fucosylation compared to healthy controls ( Fig. 2A) . The splenectomy resulted in an elevated level of IgG1 fucosylation in ITP patients, with undistinguishable IgG1 fucosylation between splenectomized ITP patients and healthy individuals. Moreover, ITP patients had a lower IgG1-Fc fucosylation than trauma-related splenectomized patients. No other significant changes were observed comparing healthy controls for any IgG subclass or glycosylation trait ( 

Splenectomy performed in ITP patients and healthy individuals due to trauma represents a unique opportunity to study the role of the spleen in control of IgG glycosylation. The key finding of our study is an increase in IgG1 fucosylation and in IgG2/3 fucosylation upon splenectomy. Although these changes in total plasma IgG are minor, with total IgG only containing ~ 6% of afucosylated IgG, they are likely to be larger and give rise to significant biological effects when looking at the antigen-specific level. For example, the ability to enhance the inflammatory response by afucosylated antigen-specific IgG was observed in fetal or neonatal alloimmune thrombocytopenia (FNAIT), dengue virus infection, COVID-19 11, 26, 29, 32 . Among all four patient groups, the otherwise healthy individuals after trauma-associated splenectomy showed the highest level of IgG1-Fc fucosylation. An increase in IgG-Fc fucosylation due to splenectomy was found in both healthy individuals as well as in ITP patients. Similar changes were seen in spherocytosis. This could either be due to, support of short lived afucosylated IgG responses generated by B cells in the spleen, or the spleen is a reservoir for long lived plasma cells 2 . Possibly, the less pronounced effect on IgG2/3 is because IgG2 is the more abundant subclass of these two (~ 32% vs 4%, respectively) 34 , and because IgG2 fucosylation is generally very high, which is in line with the predominant IgG2 response to encapsulated bacteria which do not induce afucosylated IgG responses 11, 35, 36 . However, IgG3 responses most often occur simultaneously with IgG1 responses, and the level of fucosylation of both IgG1 and IgG3 generally seem to go hand in hand 37 . It is therefore likely that the lowered effect of splenectomy on IgG2/3 afucosylation is solely due to the IgG3 fraction. Together, this points towards a pronounced role of IgG1 and IgG3 in platelet clearance compared to other IgG subclasses. Due to the prominent role and an inability to distinguish the effect size of fucosylation changes between IgG3 and IgG2, our discussion applies mainly to IgG1. Without any intervention or emerging pathology, total IgG-Fc fucosylation is largely stable throughout the adult life 38 . The precise regulation of the IgG-Fc glycosylation, and fucosylation in particular, remains still largely unelucidated. Shortly after birth, neonates make exclusively fucosylated antibodies, but appear to gradually acquire afucosylated IgG until adulthood reaching the level of 96% of IgG-Fc fucosylation 38 . Recently, we found that only antigens expressed on the surface of host cells, such as alloantigens and proteins of enveloped viruses found on cell surfaces, seem to induce afucosylated IgG responses 11 . Based on this, it is tempting to hypothesize that the gradual accumulation of afucosylated IgG seen during childhood, is the accumulation of antigenspecific IgG to enveloped viruses. However, the tendency to generate afucosylated IgG varies vastly between targets and between individuals, with IgG1 responses to cytomegalovirus being generally low and stable in However, in some patients afucosylated IgG1 is observed at seroconversion, which is associated with enhanced pathologies due to excessive inflammation in COVID-19, those responses quickly revert to fucosylated IgG in a matter of weeks 11, 32 . Conversely, alloantibodies specific for HPA-1a, causing FNAIT, or to RBC show remarkable low levels of fucosylation that are extremely stable for more than 10 years 10, 24, 26 . All in all, these disparate type of afucosylated IgG responses seem to favor both possible roles for the spleen in generating and maintaining IgG afucosylation. The afucosylation of anti-platelet antibodies has been recognized as a very important factor enhancing platelet-specific IgG effector functions through elevated affinity to FcγRIIIa/b and finally target destruction and production of proinflammatory cytokines 25, 32, 39 . The spleen, second to the liver, is recognized as one of the most important organs for removal of IgG-opsonized cells from the blood, with monocytes expressing FcγRIIIa being particularly abundant 40, 41 . Therefore, splenectomy has typically been seen as a resort focusing on removing the organ responsible for and thus preventing degradation of cells in diseases like ITP. However, it is important to realize that splenectomy not only removes an important myeloid compartment responsible of removing IgG-opsonized platelets, but also removes the major site of auto-antibody production in ITP. The splenectomy removes many autoantibody-producing cells, especially in cases of autoreactive B cells to platelets in ITP 42, 43 . Accordingly, this results in the profound elimination of anti-platelet IgG production in a splenectomized mouse model for ITP 44 . As opposed to anti-platelet IgG levels, total plasma IgG levels were not affected by splenectomy 45 . Interestingly, when targeting B cells systemically with Rituximab (anti-CD20) in ITP, afucosylated antibodies are not specifically reduced 23 , which is in line with the fact that long lived plasma cells do not express CD20 46 . A limitation in the present study is that we did not investigate antigen-specific antibodies individually.

Monitoring platelet autoantibody IgG-Fc glycosylation levels should provide further information for elucidating the mechanism of afucosylated responses in the spleen. In addition, the effect of splenectomy on composition of antigen-specific plasma cells in the bone-marrow would be valuable in a future study. In this study, total IgG1 and IgG2/3 purified from plasma of ITP patients showed decreased fucosylation when compared to healthy individuals, while galactosylation, sialylation and bisection remained similar. In previous studies, we found a similar result and effect size, but this was not statistically significant due to lower power 23 . This finding in ITP is in contrast to many autoimmunological, inflammatory and infectious conditions, where mainly galactosylation and sialylation of total IgG1 have been described to be altered 19, [47] [48] [49] . However, afucosylation of total IgG has recently been found to be elevated in autoimmune thyroid diseases 50 , similar to our ITP findings. This may suggest that the mechanism underlying the changes in IgG glycosylation in autoimmune diseases may vary depending on the disease etiology, target tissue, or the level of antigen-specific IgG glycosylation. 

Splenectomy has an effect on total plasma IgG-Fc glycosylation. ITP patients showed a lower level of total IgG-Fc fucosylation compared to healthy controls, implying that anti-platelet autoantibodies have an afucosylation phenotype in ITP, as demonstrated for FNAIT. In addition to removing a major organ responsible for removal of IgG-autoantibody opsonized cells in ITP, we also find a general splenectomy-driven increase in IgG-Fc fucosylation in humans. Altogether, our data indicate that the spleen is a significant site to generate or maintain afucosylated IgG responses.

Study participants. Plasma samples from individuals with splenectomy due to trauma, spherocytosis or immune thrombocytopenia were identified by regional general practitioners and a nationwide database 45 Mass spectrometric analysis and data processing. The total IgG glycopeptides were analyzed using an Ultimate 3000 RSLC nano-liquid chromatography system (Dionex/Thermo Fisher Scientific, Sunnyvale, CA) coupled to a Maxis Impact HD quadrupole time-of-flight (QTOF)-MS instrument (micrOTOF-Q; Bruker Daltonics, Bremen, Germany) as described previously 52 . Data were processed using the highly automated LaCy-Tools software as previously described 52, 53 . Processing parameters and the software used to compile them are listed in the supporting information. Glycopeptide compositions were selected based on literature 54 and manual inspection with Data Analysis (version 5.0; Bruker). They were verified or rejected using quality criteria provided by LaCyTools. Per IgG subclass, samples were checked for analyte quality and total signal intensity and extreme cases removed (see Supporting Information). Total area normalization was applied. Based on the normalized, directly measured N-glycan monosaccharide composition, the following derived glycosylation traits were calculated (Supplementary Table S2 ): fucosylation (fraction of fucosylated N-glycopeptides), galactosylation (fraction of galactoses per antennae of biantennary glycans), bisection (fraction of N-glycopeptides carrying a bisecting N-acetylglucosamine (GlcNAc)), sialylation (fraction of sialic acids per antennae of biantennary glycans) and sialic acid per galactose (fraction of sialic acids per galactose). Fucosylation for IgG4 could not be accurately assessed, since the exact mass of the minor IgG4 afucosylated N-glycopeptides overlapped with the more abundant IgG1 fucosylated N-glycopeptides (Supplementary Table S1 ). Moreover, the IgG4 fucosylated N-glycopeptides have the same exact mass as the afucosylated ones from IgG2/3. A study is characterized by a good analytical precision of the LC-MS method, which was assessed based on 24 replicate analysis of pool plasma standard throughout the cohort (Supplementary Fig. S1 ).

Analyses were performed in R version 3.6.4 (R Core Team). As the distribution of normalized glycan species and the derived traits deviates significantly from normality, further statistical analysis was performed using non-parametric tests 55 . A non-parametric Wilcoxon-rank test was used to compare relative intensities of the IgG-Fc glycosylation traits between pairs (non-splenectomized and splenectomized). A twosided P-value below 0.05 was considered significant. Statistical tests were only performed for IgG glycosylation traits, other data were reported descriptively. Differences in relative intensities of IgG-Fc glycosylation traits across all patient groups were evaluated for statistical significance using the non-parametric Kruskal Wallis rank sum test followed by a post-hoc Nemenyi test for pairwise comparison.

Structure and function of the spleen

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells

Marginal zone B cells: Virtues of innate-like antibody-producing lymphocytes

Post-splenectomy and hyposplenic states

B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy

Splenectomy associated changes in IgM memory B cells in an adult spleen registry cohort

Serum immunoglobulin and transferrin levels after childhood splenectomy

Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: Tailoring better vaccination strategies

Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals

Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity

Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of fc-receptor-and complementmediated-effector activities

Fc-Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity

Differential antibody glycosylation in autoimmunity: Sweet biomarker or modulator of disease activity?

Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation

Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation

Immunoglobulin G glycosylation in aging and diseases

Novel concepts of altered immunoglobulin G galactosylation in autoimmune diseases

IgG Fc N-glycosylation in Guillain-Barre syndrome treated with immunoglobulins

Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G

IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia

Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D

Low anti-RhD IgG-Fc-fucosylation in pregnancy: A new variable predicting severity in haemolytic disease of the fetus and newborn

A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy

Absence of the spleen and the occurrence of primary red cell alloimmunization in humans

Proinflammatory IgG Fc structures in patients with severe COVID-19

Antibody fucosylation predicts disease severity in secondary dengue infection

Functional attributes of antibodies, effector cells, and target cells affecting NK cell-mediated antibodydependent cellular cytotoxicity

Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Glycoproteomic analysis of antibodies

IgG subclasses and allotypes: From structure to effector functions

A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines

Recent advances in clinical glycoproteomics of immunoglobulins (Igs)

Fc-glycosylation in human IgG1 and IgG3 is similar for both total and anti-red-blood cell anti-K antibodies

Changes in healthy human IgG Fc-glycosylation after birth and during early childhood

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose

Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura

Emerging concepts in immune thrombocytopenia

Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: Splenectomy in ITP

B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia

Persistent changes in circulating white blood cell populations after splenectomy

Long-lived plasma cells and their contribution to autoimmunity

Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation

Frontline science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy

Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy

Decreased immunoglobulin G core fucosylation, a player in antibody-dependent cell-mediated cytotoxicity, is associated with autoimmune thyroid diseases

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

High-throughput analysis of IgG Fc glycopeptides by LC-MS

LaCyTools: A targeted liquid chromatography-mass spectrometry data processing package for relative quantitation of glycopeptides

Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid

I.W. and D.S. contributed equally to this work. Both I.W. and D.S. codesigned the study, conducted experiments, analyzed the data, and wrote the manuscript with support from G.V. and D.F. Both D.F. and G.V. codesigned the study, interpreted results and supervised the project. M.W. and C.E.v.d.S. discussed the study design and 

I.W. is employed by Genos Ltd. No potential conflict of interest was reported by the remaining authors.

Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-03196-w.Correspondence and requests for materials should be addressed to I.W. or G.V.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.